Haematological parameters in erythropoietic protoporphyria: A multi-national study
Rebecca K Leaf1,2, Andrea Ricci3,4,5, Benny Tran6
1Division of Hematology/Oncology, Massachusetts General Hospital, Boston, Massachusetts, USA.
British Journal of Haematology
|June 11, 2025
Summary
Erythropoietic protoporphyria (EPP) is a rare blood disorder. This study reveals key associations between protoporphyrin levels and platelet count and spleen size in EPP patients.
Area of Science:
- Biochemistry
- Hematology
- Genetics
Background:
- Erythropoietic protoporphyria (EPP) is a genetic disorder of heme biosynthesis.
- It is caused by ferrochelatase deficiency, leading to protoporphyrin IX accumulation.
- Hematological abnormalities in EPP are not well understood.
Purpose of the Study:
- To analyze hematological parameters in patients with Erythropoietic protoporphyria.
- To investigate the relationship between protoporphyrin levels and hematological indices.
- To compare hematological profiles of EPP patients with healthy controls.
Main Methods:
- Retrospective analysis of data from four large cohorts in the US and Europe.
- Detailed examination of various hematological parameters.
- Case-control analysis comparing EPP patients and controls.
Main Results:
- Protoporphyrin levels showed a significant association with platelet count.
- Elevated protoporphyrin levels correlated with increased spleen size.
- Significant differences in hematological indices were observed between EPP patients and controls.
Conclusions:
- EPP is associated with distinct hematological alterations.
- Platelet count and spleen size are potential indicators related to protoporphyrin accumulation in EPP.
- Further research into EPP pathophysiology and management is warranted.
More Related Videos
11:59Detection of Residual Donor Erythroid Progenitor Cells after Hematopoietic Stem Cell Transplantation for Patients with Hemoglobinopathies
Published on: September 6, 2017
7.3K
07:40Preparation of Peripheral Blood Mononuclear Cell Pellets and Plasma from a Single Blood Draw at Clinical Trial Sites for Biomarker Analysis
Published on: March 20, 2021
16.6K
